We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DNA Minicircle Technique for Stem Cell Reprogramming to Be Commercialized

By LabMedica International staff writers
Posted on 29 Jun 2010
Pluripotent stem cells can be generated from adult human adipose stem cells by using nonintegrating minicircle DNA plasmids that contain the minimum amount of DNA required to reprogram the cells.

The minicircle method has several advantages over conventional virus or bacterial plasmid procedures for cell reprogramming. More...
DNA minicircles do not integrate into the cell's genome and are naturally lost as the cells divide, overcoming some the safety concerns associated with current reprogramming methods. Since minicircles contain no bacterial plasmid backbone DNA, they are able to evade silencing mechanisms that cells naturally use against foreign DNA.

The DNA minicircles are a type of vector that can be either transfected or electroporated into cells to allow for expression of the reprogramming factors. The mini-circle plasmid remains in the cytoplasm of the cell and is eventually lost from the dividing cells. This approach eliminates integration-site expression variability and mutagenesis that is a drawback to viral approaches that have been used to date.

A paper describing the use of DNA minicircles was published in the March 1, 2010, issue of the journal Nature Methods by investigators at Stanford University (Palo Alto, CA, USA). Now it has been announced that the biotechnology company STEMCELLS Technologies Inc. (Vancouver, Canada) has obtained a license from Stanford University to exploit the technology on a commercial basis and intends to market the DNA minicircles as a product called "STEMcircles”.
"The addition of nonviral, nonintegrating STEMcircle reprogramming vectors to our current product offering is an exciting new opportunity for STEMCELL Technologies as a leading provider of standardized, innovative and high quality tools for pluripotent stem cells,” said Alaine Maxwell, product manager of pluripotent stem cell biology at STEMCELL Technologies.

Related Links:
Stanford University
STEMCELLS Technologies Inc.



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.